Every 10-K that Translational Development Acquisition Corp. Units (TDACU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow TDACU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TDACU filings page.
Translational Development Acquisition Corp. filed Amendment No. 2 to its 2025 annual report to revise its conclusion on disclosure controls and procedures. Management, including the chief financial officer, now concludes that as of December 31, 2025 these disclosure controls and procedures were not effective.
The company states that internal control over financial reporting, assessed using the COSO 2013 framework, was effective as of December 31, 2025, and notes no material changes in these controls during the most recent fiscal quarter. The amendment also adds updated Section 302 and Section 906 Sarbanes-Oxley officer certifications, with no other changes to the original Form 10-K or prior amendment.
Translational Development Acquisition Corp. filed Amendment No. 1 to its 2025 annual report to update its controls and procedures disclosure. The company is responding to an SEC comment letter by replacing Item 9A and providing new officer certifications, while leaving all other 10-K disclosures unchanged.
Management, including the chief financial officer, evaluated disclosure controls and procedures as of December 31, 2025 and concluded they were effective. Using the COSO 2013 framework, management also determined internal control over financial reporting was effective, with no material changes during the most recent fiscal quarter.
The filing notes aggregate market value of Class A ordinary shares of $177,675,000 as of June 30, 2025. As of March 30, 2026, 17,250,000 Class A ordinary shares and 4,657,500 Class B ordinary shares were issued and outstanding.
Translational Development Acquisition Corp. reports its 2025 results as a blank check company focused on completing an initial business combination. It completed an IPO of 17,250,000 units at $10.00 each, plus 7,075,000 private placement warrants at $1.00, placing $174,225,000 into a trust at $10.10 per public share.
At December 31, 2025, investments in the trust totaled $181,657,311 and the company recorded net income of $6,362,427, driven by $7,306,965 of dividends on trust investments and $944,538 of operating costs. Cash outside the trust was $29,787 with a working capital deficit of $504,608.
The company has until June 24, 2026 to complete a business combination or redeem public shares and liquidate. Management discloses substantial doubt about its ability to continue as a going concern absent a timely deal or further sponsor support, while highlighting shareholder redemption protections and the sponsor’s limited indemnity for certain creditor claims.